Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Ascendis Pharma Reports Second Quarter 2026 Financial Results
GlobeNewswire, Inc.
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient enrollments in the U.S. – Substantial...
Zealand Pharma Announces Financial Results for the First Half of 2026
GlobeNewswire, Inc.
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of...
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
GlobeNewswire, Inc.
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its...
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a...
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
GlobeNewswire, Inc.
Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Rinn Pharma & Biopharma Expands European Research Collaboration Through NordicPharmaTrain Partnership
EIN Presswire
Rinn Pharma & Biopharma expanding collaborative research and training across the Nordic and European innovation landscape.
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
GlobeNewswire, Inc.
Press Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
GlobeNewswire, Inc.
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and...
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
GlobeNewswire, Inc.
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide,...
H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development
GlobeNewswire, Inc.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- H1 today announced a new partnership with Novo Nordisk to improve clinical development in the age of AI. The partnership aims to develop proprietary AI-ready data and AI-powered clinical development...
Randomized U.S. Trial Finds Autonomous System Improves Precision of Hospital Oxygen Therapy
GlobeNewswire, Inc.
Copenhagen, Denmark, Aug. 03, 2026 (GLOBE NEWSWIRE) -- — O2matic ApS today announced results from a randomized, multicenter U.S. clinical trial showing that hospitalized patients receiving autonomous oxygen titration with the O2matic PRO 100 spent...
NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer
GlobeNewswire, Inc.
STEVENAGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases,...
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
GlobeNewswire, Inc.
Company announcement No. 36 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 31, 2026) Copenhagen, Denmark, August 3, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality
GlobeNewswire, Inc.
COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience...
BioAgeDiagnostics Strengthens Global Medical Advisory Board with Dr. Stuart M. Diamond
EIN Presswire
Board-certified longevity physician and surgeon joins BioAgeDiagnostics to accelerate the global adoption of precision longevity diagnostics.
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
GlobeNewswire, Inc.
Company announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Anteris Technologies Announces Results for the Second Quarter of 2026
GlobeNewswire, Inc.
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing...
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
GlobeNewswire, Inc.
-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator...
NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness
GlobeNewswire, Inc.
New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular transmission and muscle function NMD Pharma is...
Enable Me Highlights VA-Contracted Mobility Chairs to Support US Veterans
EIN Presswire
Through a dedicated FSS contract, Enable Me provides U.S. veterans with specialized VELA Chairs at no cost to qualified individuals via VA benefits.
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.